The FDA posted a summary of observations made from the Agency’s inspection of a Regeneron (REGN) facility in Ireland that was conducted from March 6-10 and 13-14 of 2023 to its website.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- QQQ ETF Update, 11/21/2024
- Morgan Stanley, Comerica upgraded: Wall Street’s top analyst calls
- Regeneron, Sanofi announce FDA accepts Dupixent sBLA for review
- Wolfe Research starts Regeneron at Outperform, sees ‘attractive entry point’
- Regeneron initiated with an Outperform at Wolfe Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
